PV24 Speakers

Subject to change.

 

 

image

Monica de Baca, MD

VP Medical Affairs, Sysmex-America, Inc., Sysmex America, Inc.

Dr de Baca is a board-certified anatomic and clinical (AP/CP) pathologist, hematopathologist and ophthalmologist. She is the Vice President for Medical Affairs at Sysmex America, Inc., and co-founder of MD Path, LLC, a pathology consulting service.  She earned her medical degree at the Universidad del Salvador in Buenos Aires, Argentina, and completed her ophthalmology residency at Achenbach Hospital, Königs Wusterhausen and E.-v.-Bergmann Clinic in Potsdam, Germany. She completed a transitional year at Texas Tech University before receiving her AP/CP residency and hematopathology fellowship training at Thomas Jefferson University Hospitals in Philadelphia. Before joining Sysmex, Dr. de Baca has had roles as the director of Hematopathology and director of CLIA labs in private practice, academic practice and industry on the East Coast, the Plains and in the Pacific Northwest.. 

 

Dr. de Baca is active in numerous medical and pathology organizations, including the United States and Canadian Academy of Pathology, American Society of Hematology, Society for Hematopathology and Association of Diagnostic and Laboratory Medicine.She is a past president of the Association for Pathology Informatics and served on the Clinical Laboratory Improvement Advisory Committee (CLIAC), which reports to CDC and HHS.

 

Currently on the Board of Governors of the College of American Pathologists, Dr. de Baca has been an active member of several of its councils and committees; she has served as the Council on Education chair, Artificial Intelligence Committee vice chair and as a member of the Information Technology Leadership, Informatics and Diversity, Equity, Inclusion committees. She was the founding chair of the Pathology Electronic Reporting Committee and served as a member of the Cancer Committee where she co-authored several CAP Cancer Checklists. Dr. de Baca represented CAP as a liaison to SNOMED International and the North American Association of Central Cancer Registries. Dr. de Baca currently chairs the CAP’s Council on Informatics and Pathology Innovation.

 

 

SESSIONS

Informatics and Pathology Innovation Highlights of the College of American Pathologists
   Mon, Nov 4
   03:30PM - 03:50PM ET
  Regency P

This presentation is designed for those interested in understanding the strategic initiatives of the College of American Pathologists (CAP) regarding Digital Pathology (DP) and AI reimbursement. It will also address the impact of recent FDA Laboratory Developed Test (LDT) rules on pathology, DP, and AI. Attendees will gain insights into the resources CAP provides in these areas and learn about CAP's efforts to advance the practice and science of DP and AI. Additionally, the presentation will explore how the pathology community can collaborate to advance various areas, including implementation, quality improvement, standardization, cancer protocols, electronic reporting, and the regulatory science of DP and AI.The CAP established the Council on Informatics and Pathology Innovation (CIPI) in 2022. It is charged to identify and recommend strategic direction on current and emerging medical information science, date science, and computational technologists that could impact the practice of pathology; provide informatics domain information and expertise to the CAP in furtherance of its programs and mission; and support appropriate engagement with external stakeholders. CIPI has embarked on numerous initiatives in education, quality, proficiency testing, and regulatory science of DP, AI, and beyond. The leadership and resources provided by CIPI and its various committee are valuable to pathologists and laboratories undergoing a digital transformation. In addition, the CAP's Council on Government and Professional Affairs (CGPA) is working diligently on behalf of pathologists to identify current and emerging issues in the legislative, regulatory, and private sector arenas that may impact the practice of pathology; to develop policies and strategies to positively influence these issues to benefit patients and pathologists; and to implement these policies and strategies by educating pathologists, conducting advocacy programs and maintaining liaison with health-related organization.The presenters and panelists are pathologists and the chairs of the CIPI, CGPA, and Digital and Computational Pathology Committee. A Q&A session will follow the presentation. This one-hour session aims to provide valuable insights and foster collaboration among pathologists and laboratories experiencing a digital transformation. The leadership and resources offered by CAP, through CIPI and CGPA, are instrumental in navigating the evolving landscape of digital pathology and AI.

 

Learning Objectives

  1. Understand the CAP’s leadership on advocating for pathologists and laboratory medicine on regulatory issues impacting pathology, especially on DP and AI.
  2. Understand the CAP’s strategy in DP and AI reimbursement.
  3. Learn about resources provided by CAP on Informatics and Pathology innovation.
Chat bot